Arcturus Therapeutics Holdings Inc (ARCT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $240.96M
Last updated: Nov 17, 2026 at 11:04 AM ET
Arcturus Therapeutics Holdings Inc (ARCT) Stock Forecast
Analysts expect Arcturus Therapeutics Holdings (ARCT) to earn -$2.90 per share in the fiscal year ending Dec 31, 2026, on revenue of $28.35M. Of 13 analysts, 11 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.08, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 85% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 7.7% |
| Buy | 10 | 76.9% |
| Hold | 2 | 15.4% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 6.1%.
- Fiscal year ending Dec 31, 2026
- -$2.90
- EPS consensus, revenue $28.35M
- Fiscal year ending Dec 31, 2027
- -$3.33
- EPS consensus, revenue $30.09M
- Next report
- Mar 1, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.90 | -$3.01 to -$2.73 | 7 | $28.35M | $24.50M to $33.52M | 9 |
| Dec 31, 2027 | -$3.33 | -$4.38 to -$1.99 | 10 | $30.09M | $3.00M to $127.81M | 13 |
Quarterly Estimates
The EPS consensus rises from -$0.92 for the quarter ending Dec 31, 2026 to -$0.88 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.92 | -$1.52 to -$0.55 | 15 | $5.22M | $1.42M to $20.72M | 15 |
| Mar 31, 2027 | -$0.88 | -$1.05 to -$0.76 | 4 | $1.95M | $600000 to $3.83M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 3 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.34.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.90 | -$3.45 | -$3.42 | -$3.42 | -$3.34 | N/A |
| Fiscal year ending Dec 31, 2027 | -$3.33 | -$3.70 | -$3.62 | -$3.61 | -$3.83 | N/A |
| Quarter ending Mar 31, 2027 | -$0.88 | -$0.83 | -$0.83 | -$0.83 | -$0.96 | N/A |
Frequently Asked Questions About ARCT
What is the ARCT stock forecast?
Consensus analyst estimates put Arcturus Therapeutics Holdings's EPS at -$2.90 for the fiscal year ending Dec 31, 2026, on revenue of $28.35M. The consensus rating from 13 analysts is Buy.
How do analysts rate ARCT stock?
Of 13 analysts covering Arcturus Therapeutics Holdings, 1 rates it Strong Buy, 10 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ARCT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.90, with estimates from -$3.01 to -$2.73 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.33, with estimates from -$4.38 to -$1.99 from 10 analysts.
What revenue do analysts expect from Arcturus Therapeutics Holdings next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $28.35M, with estimates from $24.50M to $33.52M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $30.09M, with estimates from $3.00M to $127.81M.
How many analysts cover ARCT?
13 analysts rate Arcturus Therapeutics Holdings stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ARCT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors